MCP4 was a novel human β chemokine, which had a strong chemotactic effect on monocytes and eosinophils, inducing inflammation upon binding to CC chemokine receptor 3[35,36] and exhibited low expression in PCa serum samples.[37] The results of the present MR analysis concluded that MCP4 is a risk factor for PCa, and it has been proved that MCP4 has low expression in prostate patients. The gene discussed is CCL13; the disease is posterior cortical atrophy.